The retina as a window to the brain - From eye research to CNS disorders

Nature Reviews Neurology

Volumn 9, Issue 1, 2013, Pages 44-53

  London, Anat ^a   Benhar, Inbal ^a   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HUMANIN; LEVODOPA;

ALZHEIMER DISEASE; BLOOD RETINA BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; GENETIC ANALYSIS; GLAUCOMA; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOMA; MICROANGIOPATHY; MULTIPLE SCLEROSIS; NERVE FIBER; OLIGODENDROGLIA; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RETINA; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; VISUAL ACUITY; VISUAL IMPAIRMENT; WHITE MATTER;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; EYE DISEASES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMAGING; PROGNOSIS; RESEARCH; RETINA; SPINAL CORD; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84871922710     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.227     Document Type: Review

References (139)

1. Dowling, J. E. in Encyclopedia of the Human Brain, Vol. 4 (ed. Ramachandran, V.) 217-235 (Academic Press, San Diego, 2002).
2. Berson, D. M. in The Senses: A Comprehensive Reference, Vol. 1 (eds Basbaum, A. I. et al.) 491-519 (Elsevier, New York, 2008).
3. Faden, A. I. & Salzman, S. Pharmacological strategies in CNS trauma. Trends Pharmacol. Sci. 13, 29-35 (1992).
4. Schwartz, M., Belkin, M., Yoles, E. & Solomon, A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma 5, 427-432 (1996).
5. Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N. & Beattie, M. S. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat. Med. 3, 73-76 (1997).
6. Levkovitch-Verbin, H. et al. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 42, 975-982 (2001).
7. Levkovitch-Verbin, H. et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest. Ophthalmol. Vis. Sci. 44, 3388-3393 (2003).
8. Yoles, E. & Schwartz, M. Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp. Neurol. 153, 1-7 (1998).
9. Benowitz, L. & Yin, Y. Rewiring the injured CNS: lessons from the optic nerve. Exp. Neurol. 209, 389-398 (2008).
10. Vidal-Sanz, M., Bray, G. M., Villegas-Perez, M. P., Thanos, S. & Aguayo, A. J. Axonal regeneration and synapse formation in the superior colliculus by retinal ganglion cells in the adult rat. J. Neurosci. 7, 2894-2909 (1987).
11. Keirstead, S. A. et al. Electrophysiologic responses in hamster superior colliculus evoked by regenerating retinal axons. Science 246, 255-257 (1989).
12. Villegas-Perez, M. P., Vidal-Sanz, M., Bray, G. M. & Aguayo, A. J. Influences of peripheral nerve grafts on the survival and regrowth of axotomized retinal ganglion cells in adult rats. J. Neurosci. 8, 265-280 (1988).
13. Moalem, G. et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5, 49-55 (1999).
14. Kipnis, J. et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl Acad. Sci. USA 97, 7446-7451 (2000).
15. Lingor, P. et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 103, 181-189 (2007).
16. Schwab, M. E. Nogo and axon regeneration. Curr. Opin. Neurobiol. 14, 118-124 (2004).
17. Lehmann, M. et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J. Neurosci. 19, 7537-7547 (1999).
18. Fischer, D., He, Z. & Benowitz, L. I. Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state. J. Neurosci. 24, 1646-1651 (2004).
19. Silver, J. & Miller, J. H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146-156 (2004).
20. Rolls, A. et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 5. e171 (2008).
21. Filbin, M. T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 4, 703-713 (2003).
22. David, S. & Aguayo, A. J. Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 214, 931-933 (1981).
23. Streilein, J. W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3, 879-889 (2003).
24. Kaur, C., Foulds, W. S. & Ling, E. A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res. 27, 622-647 (2008).
25. Wilbanks, G. A. & Streilein, J. W. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-β. Eur. J. Immunol. 22, 1031-1036 (1992).
26. Taylor, A. W. & Streilein, J. W. Inhibition of antigen-stimulated effector T cells by human cerebrospinal fluid. Neuroimmunomodulation 3, 112-118 (1996).
27. Cheung, N. et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 133, 1987-1993 (2010).
28. Wong, T. Y. et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358, 1134-1140 (2001).
29. Wong, T. Y. et al. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv. Ophthalmol. 46, 59-80 (2001).
30. Wong, T. Y. et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 288, 67-74 (2002).
31. Kalesnykas, G., Tuulos, T., Uusitalo, H. & Jolkkonen, J. Neurodegeneration and cellular stress in the retina and optic nerve in rat cerebral ischemia and hypoperfusion models. Neuroscience 155, 937-947 (2008).
32. Baker, M. L., Hand, P. J., Wang, J. J. & Wong, T. Y. Retinal signs and stroke: revisiting the link between the eye and brain. Stroke 39, 1371-1379 (2008).
33. Patton, N. et al. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J. Anat. 206, 319-348 (2005).
34. Wardlaw, J. M. et al. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann. Neurol. 65, 194-202 (2009).
35. Wardlaw, J. M., Sandercock, P. A., Dennis, M. S. & Starr, J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34, 806-812 (2003).
36. Leibowitz, U. & Alter, M. Optic nerve involvement and diplopia as initial manifestations of multiple sclerosis. Acta Neurol. Scand. 44, 70-80 (1968).
37. McDonald, W. I. & Barnes, D. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J. Neurol. Neurosurg. Psychiatry 55, 747-752 (1992).
38. Sorensen, T. L., Frederiksen, J. L., Bronnum-Hansen, H. & Petersen, H. C. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology 53, 473-478 (1999).
39. Patel, S. J. & Lundy, D. C. Ocular manifestations of autoimmune disease. Am. Fam. Physician 66, 991-998 (2002).
40. Soderstrom, M. Optic neuritis and multiple sclerosis. Acta Ophthalmol. Scand. 79, 223-227 (2001).
41. Ghezzi, A. et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J. Neurol. 246, 770-775 (1999).
42. Firth, D. The case of Augustus d'Este (1794-1848): the first account of disseminated sclerosis: (Section of the History of Medicine). Proc. R. Soc. Med. 34, 381-384 (1941).
43. Fisher, J. B. et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113, 324-332 (2006).
44. Monteiro, M. L., Fernandes, D. B., Apostolos-Pereira, S. L. & Callegaro, D. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using fourier-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 53, 3959-3966 (2012).
45. Green, A. J., McQuaid, S., Hauser, S. L., Allen, I. V. & Lyness, R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 133, 1591-1601 (2010).
46. Kerrison, J. B., Flynn, T. & Green, W. R. Retinal pathologic changes in multiple sclerosis. Retina 14, 445-451 (1994).
47. Gundogan, F. C., Tas, A., Erdem, U. & Sobaci, G. Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain 134. e171; author reply e172 (2011).
48. Masson, G., Mestre, D. & Blin, O. Dopaminergic modulation of visual sensitivity in man. Fundam. Clin. Pharmacol. 7, 449-463 (1993).
49. Santano, C., Pérez de Lara, M. & Pintor, J. in Studies on Experimental Models (eds Basu, S. & Wiklund, L.) 221-250 (Humana Press, New York, 2011).
50. Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. The retina in Parkinson's disease. Brain 132, 1128-1145 (2009).
51. Devos, D. et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 65, 1107-1110 (2005).
52. Moschos, M. M. et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur. J. Ophthalmol. 21, 24-29 (2011).
53. Inzelberg, R., Ramirez, J. A., Nisipeanu, P. & Ophir, A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 44, 2793-2797 (2004).
54. Altintas, O., Iseri, P., Ozkan, B. & Caglar, Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc. Ophthalmol. 116, 137-146 (2008).
55. Hajee, M. E. et al. Inner retinal layer thinning in Parkinson disease. Arch. Ophthalmol. 127, 737-741 (2009).
56. Onofrj, M., Ghilardi, M. F., Basciani, M. & Gambi, D. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J. Neurol. Neurosurg. Psychiatry 49, 1150-1159 (1986).
57. Chiu, K. et al. Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr.) 34, 633-649 (2012).
58. Guo, L., Duggan, J. & Cordeiro, M. F. Alzheimer's disease and retinal neurodegeneration. Curr. Alzheimer Res. 7, 3-14 (2010).
59. Danesh-Meyer, H. V., Birch, H., Ku, J. Y., Carroll, S. & Gamble, G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 67, 1852-1854 (2006).
60. Hinton, D. R., Sadun, A. A., Blanks, J. C. & Miller, C. A. Optic-nerve degeneration in Alzheimer's disease. N. Engl. J. Med. 315, 485-487 (1986).
61. Blanks, J. C., Hinton, D. R., Sadun, A. A. & Miller, C. A. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 501, 364-372 (1989).
62. Blanks, J. C., Torigoe, Y., Hinton, D. R. & Blanks, R. H. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging 17, 377-384 (1996).
63. Blanks, J. C. et al. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol. Aging 17, 385-395 (1996).
64. Parisi, V. et al. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin. Neurophysiol. 112, 1860-1867 (2001).
65. Berisha, F., Feke, G. T., Trempe, C. L., McMeel, J. W. & Schepens, C. L. Retinal abnormalities in early Alzheimer's disease. Invest. Ophthalmol. Vis. Sci. 48, 2285-2289 (2007).
66. Iseri, P. K., Altinas, O., Tokay, T. & Yuksel, N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 26, 18-24 (2006).
67. Sadun, A. A. & Bassi, C. J. Optic nerve damage in Alzheimer's disease. Ophthalmology 97, 9-17 (1990).
68. Goldstein, L. E. et al. Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361, 1258-1265 (2003).
69. Ning, A., Cui, J., To, E., Ashe, K. H. & Matsubara, J. Amyloid-β deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci. 49, 5136-5143 (2008).
70. Liu, B. et al. Amyloid-peptide vaccinations reduce β-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am. J. Pathol. 175, 2099-2110 (2009).
71. Gasparini, L. et al. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol. Aging 32, 419-433 (2011).
72. Koronyo-Hamaoui, M. et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54 (Suppl. 1), S204-S217 (2011).
73. Buggage, R. R., Chan, C. C. & Nussenblatt, R. B. Ocular manifestations of central nervous system lymphoma. Curr. Opin. Oncol. 13, 137-142 (2001).
74. Buckingham, B. P. et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J. Neurosci. 28, 2735-2744 (2008).
75. Calkins, D. J. A neurological perspective on glaucoma. Glaucoma Today [online], http://bmctoday.net/glaucomatoday/2008/09/article.asp?f=GT0908-03.php (2008).
76. Jakobs, T. C., Libby, R. T., Ben, Y., John, S. W. & Masland, R. H. Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J. Cell Biol. 171, 313-325 (2005).
77. Braak, H. & Del Tredici, K. Nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916-1925 (2008).
78. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
79. Fischer, L. R. & Glass, J. D. Axonal degeneration in motor neuron disease. Neurodegener. Dis. 4, 431-442 (2007).
80. Gupta, N. & Yucel, Y. H. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 18, 110-114 (2007).
81. Yucel, Y. & Gupta, N. Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog. Brain Res. 173, 465-478 (2008).
82. Yin, H., Chen, L., Chen, X. & Liu, X. Soluble amyloid β oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med. Hypotheses 71, 77-80 (2008).
83. Janciauskiene, S. & Krakau, T. Alzheimer's peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer's disease. Acta Ophthalmol. Scand. 79, 328-329 (2001).
84. Yoneda, S. et al. Vitreous fluid levels of β-amyloid(1-42) and tau in patients with retinal diseases. Jpn J. Ophthalmol. 49, 106-108 (2005).
85. Gupta, N., Fong, J., Ang, L. C. & Yucel, Y. H. Retinal tau pathology in human glaucomas. Can. J. Ophthalmol. 43, 53-60 (2008).
86. Goldblum, D., Kipfer-Kauer, A., Sarra, G. M., Wolf, S. & Frueh, B. E. Distribution of amyloid precursor protein and amyloid-β immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest. Ophthalmol. Vis. Sci. 48, 5085-5090 (2007).
87. Guo, L. et al. Targeting amyloid-β in glaucoma treatment. Proc. Natl Acad. Sci. USA 104, 13444-13449 (2007).
88. Johnson, L. V. et al. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 11830-11835 (2002).
89. Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski, J. Q. & Dunaief, J. L. Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol. Vis. 9, 184-190 (2003).
90. Yoshida, T. et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J. Clin. Invest. 115, 2793-2800 (2005).
91. Isas, J. M. et al. Soluble and mature amyloid fibrils in drusen deposits. Invest. Ophthalmol. Vis. Sci. 51, 1304-1310 (2010).
92. Mullins, R. F., Russell, S. R., Anderson, D. H. & Hageman, G. S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835-846 (2000).
93. Luibl, V. et al. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Invest. 116, 378-385 (2006).
94. Klomp, L. W. & Gitlin, J. D. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5, 1989-1996 (1996).
95. Ke, Y. & Ming Qian, Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2, 246-253 (2003).
96. Hochstrasser, H. et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63, 1912-1917 (2004).
97. Farkas, R. H. et al. Increased expression of iron-regulating genes in monkey and human glaucoma. Invest. Ophthalmol. Vis. Sci. 45, 1410-1417 (2004).
98. Levin, L. A. & Geszvain, K. M. Expression of ceruloplasmin in the retina: induction after optic nerve crush. Invest. Ophthalmol. Vis. Sci. 39, 157-163 (1998).
99. Ishiura, H. et al. Posterior column ataxia with retinitis pigmentosa in a Japanese family with a novel mutation in FLVCR1. Neurogenetics 12, 117-121 (2011).
100. Rajadhyaksha, A. M. et al. Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa. Am. J. Hum. Genet. 87, 643-654 (2010).
101. London, A. et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J. Exp. Med. 208, 23-39 (2011).
102. Shechter, R. et al. Toll-like receptor 4 restricts retinal progenitor cell proliferation. J. Cell Biol. 183, 393-400 (2008).
103. Yoles, E. et al. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21, 3740-3748 (2001).
104. Anchan, R. M., Reh, T. A., Angello, J., Balliet, A. & Walker, M. EGF and TGF-α stimulate retinal neuroepithelial cell proliferation in vitro. Neuron 6, 923-936 (1991).
105. Yin, Y. et al. Oncomodulin links inflammation to optic nerve regeneration. Proc. Natl Acad. Sci. USA 106, 19587-19592 (2009).
106. Zaverucha-do-Valle, C. et al. Bone marrow mononuclear cells increase retinal ganglion cell survival and axon regeneration in the adult rat. Cell Transplant. 20, 391-406 (2011).
107. Wong, T. Y. Is retinal photography useful in the measurement of stroke risk? Lancet Neurol. 3, 179-183 (2004).
108. De Silva, D. A. et al. Retinal microvascular changes and subsequent vascular events after ischemic stroke. Neurology 77, 896-903 (2011).
109. Frohman, E. M., Balcer, L. J. & Calabresi, P. A. Multiple sclerosis: can retinal imaging accurately detect optic neuritis? Nat. Rev. Neurol. 6, 125-126 (2010).
110. Naismith, R. T. et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 73, 46-52 (2009).
111. Petzold, A. et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 9, 921-932 (2010).
112. Henderson, A. P. et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 131, 277-287 (2008).
113. Gordon-Lipkin, E. et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69, 1603-1609 (2007).
114. Grazioli, E. et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J. Neurol. Sci. 268, 12-17 (2008).
115. Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106-2112 (2004).
116. Ratchford, J. N. et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73, 302-308 (2009).
117. Nakamura, M. et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch. Clin. Exp. Ophthalmol. 248, 1777-1785 (2010).
118. Naismith, R. T. et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 72, 1077-1082 (2009).
119. Kesler, A., Vakhapova, V., Korczyn, A. D., Naftaliev, E. & Neudorfer, M. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin. Neurol. Neurosurg. 113, 523-526 (2011).
120. Paquet, C. et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 420, 97-99 (2007).
121. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
122. Melnikova, I. Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 6, 341-342 (2007).
123. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
124. Ding, J. D. et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc. Natl Acad. Sci. USA 108. E279-E287 (2011).
125. Ding, J. D. et al. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 48, 339-345 (2008).
126. Niikura, T., Hashimoto, Y., Tajima, H. & Nishimoto, I. Death and survival of neuronal cells exposed to Alzheimer's insults. J. Neurosci. Res. 70, 380-391 (2002).
127. Men, J., Zhang, X., Yang, Y. & Gao, D. An AD-related neuroprotector rescues transformed rat retinal ganglion cells from CoCl2-induced apoptosis. J. Mol. Neurosci. 47, 144-149 (2012).
128. Frenkel, D., Maron, R., Burt, D. S. & Weiner, H. L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 2423-2433 (2005).
129. Frenkel, D. et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J. Immunol. 171, 6549-6555 (2003).
130. Ben Simon, G. J., Bakalash, S., Aloni, E. & Rosner, M. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. Am. J. Ophthalmol. 141, 1105-1111 (2006).
131. Schori, H. et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl Acad. Sci. USA 98, 3398-3403 (2001).
132. Mitne, S. et al. The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation. Clin. Ophthalmol. 5, 991-997 (2011).
133. US National Library of Medicine. A randomized, double-blind, placebo-controlled, multicenter study of the effects of glatiramer acetate (GA) on the retinal nerve fiber layer (RNFL) and visual function in patients with a first episode of acute optic neuritis (AON). US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00856635? term=glatiramer±acetate&rank=21 (2011).
134. US National Library of Medicine. Copaxone in age related macular degeneration. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00466076?term=glatiramer±acetate&rank=33 (2007).
135. US National Library of Medicine. Weekly vaccination with copaxone as a potential therapy for dry age-related macular degeneration. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00541333?term= glatiramer+acetate&rank=46 (2008).
136. Yucel, Y. H. et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch. Ophthalmol. 124, 217-225 (2006). 137.
137. [No authors listed] Allergan reports fourth quarter operating results and announces restructuring. Allergan.com [online], http://agn.client.shareholder. com/earningsreleasedetail.cfm?ReleaseID=363526 (2008).
138. Samples, J. R. in Ophthalmology Management (Wolters Kluwer Pharma Solutions Inc., Ambler, PA, 2011).
139. Wostyn, P., Audenaert, K. & De Deyn, P. P. Alzheimer's disease: cerebral glaucoma? Med. Hypotheses 74, 973-977 (2010).